CVKD — Cadrenal Therapeutics Share News
0.000.00%
Last trade - 00:00Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
Cadrenal rises as blood clot drug cuts risk in mid-stage study
NASDAQ RESUMED AT 11:19 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:14 AM
Brief: Cadrenal Therapeutics To Submit FDA Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease
Brief: Cadrenal Therapeutics Says Matthew Szot Steps Down As CFO - SEC Filing
Brief: Cadrenal Therapeutics Inc - Prospectus Filed For Resale Of Up To 1.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing
NASDAQ RESUMED AT 10:48 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:43 AM
U.S. RESEARCH ROUNDUP-3M, CME Group, Transdigm Group
NASDAQ RESUMED AT 03:34 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:29 PM
Brief: Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005
Brief: Cadrenal Therapeutics To Conduct Partnering And Investor Meetings
Brief: Cadrenal Therapeutics Acquires VLX-1005, A First-In-Class Phase 2 12-LOX Inhibitor For Patients With Heparin-Induced Thrombocytopenia
Brief: Cadrenal Therapeutics Appoints Dr. Lee Golden To Board Of Directors